Abstract
In this study, QSAR modeling was performed for predicting the IC50 value for a set of HIV-1 integrase inhibitors using multiple regression and partial least square method obtaining an optimized model for each method. These models were used to predict a set of test compounds obtained by performing a chemical similarity search of the training set from the NCBI PubChem database subjected to the Lipinski rule of five filters. The predicted IC50 value for the test set compounds was further analyzed for molecular docking simulation against HIV-1 integrase revealing that the test set compounds have a more binding affinity than the training set compounds and the market approved drug raltegravir. The stability of the docked compounds (protein–ligand complexes) was further validated by performing molecular dynamics simulations for 20 ns using Gromacs 5.0, and the RMSD backbone was analyzed. Last, the ADME–toxicity analysis was carried out for the top docking hit compounds and the market approved drug raltegravir revealing that the docked compounds have enhanced pharmacological parameters than raltegravir.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Network Modeling Analysis in Health Informatics and Bioinformatics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.